2024
Endometrial stromal cell signaling and microRNA exosome content in women with adenomyosis
Zipponi M, Cacciottola L, Camboni A, Stratopoulou C, Taylor H, Dolmans M. Endometrial stromal cell signaling and microRNA exosome content in women with adenomyosis. Molecular Human Reproduction 2024, 31: gaae044. PMID: 39673794, DOI: 10.1093/molehr/gaae044.Peer-Reviewed Original ResearchStromal cell signalsMenstrual phaseHealthy subjectsPresence of endometrial glandsPathogenesis of adenomyosisCompared to controlsEndometrial biopsyEndometrial glandsEutopic endometriumStromal compartmentAdenomyosisAdenomyosis developmentMolecular mechanismsCell signalingLesion establishmentStromal cellsNanoparticle tracking analysisFlow cytometryEpithelial glandsParacrine signalingQuality of lifeSecreted exosomesIntercellular communicationExosomal contentsReproductive healthWomen with endometriosis in the United States: National Survey of Family Growth, 2011–2019
Al-Lami R, Taha S, Jalloul R, Taylor H. Women with endometriosis in the United States: National Survey of Family Growth, 2011–2019. Journal Of Endometriosis And Uterine Disorders 2024, 8: 100081. DOI: 10.1016/j.jeud.2024.100081.Peer-Reviewed Original ResearchNational Survey of Family GrowthAssociated with infertilityFamily GrowthRates of functional impairmentQuality of lifeNational surveyWeighted prevalencePrevalence of infertilityPain associated with endometriosisLongitudinal population-based studyAssociated with endometriosisPrevalence of endometriosisFunctional impairmentNationally Representative SamplePopulation-based studyDiminished quality of lifeLogistic regression analysisSample of womenCross-sectional studyCharacteristics of womenInfertile womenEndometriosisReproductive factorsU.S. womenAnalytic sample
2023
Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set
Cooper N, Rivas C, Munro M, Critchley H, Clark T, Matteson K, Papadantonaki R, Yorke S, Tan A, Rodriguez M, Bongers M, Al‐Hendy A, Bahamondes L, Connolly A, Farquhar C, Valbrun T, Hickey M, Taylor H, Toub D, Vannuccini S, Iliodromiti S, Khan K. Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG An International Journal Of Obstetrics & Gynaecology 2023, 130: 1337-1345. PMID: 37055716, DOI: 10.1111/1471-0528.17473.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingCore outcomeFinal COSMenstrual bleedingClinical trialsConsensus meetingSystematic reviewSeverity of dysmenorrhoeaNumber of patientsPotential core outcomesInternational Consensus MeetingQuality of lifeDelphi surveyTwo-round Delphi surveyAdverse eventsBlood lossHemoglobin levelsFuture trialsGynecology DepartmentCOMET InitiativePatient satisfactionClinical guidelinesResource settingsOnline international surveyFurther treatment
2021
O-135 Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials
Taylor H, Donnez J, Petraglia F, Danielsson K, Renner S, Bestel E, Gotteland J, Humberstone A, Garner E. O-135 Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials. Human Reproduction 2021, 36: deab126.060. DOI: 10.1093/humrep/deab126.060.Peer-Reviewed Original ResearchHeavy menstrual bleedingQuality of lifePhase 3 trialWeeks of treatmentUterine fibroidsPain scoresSecondary endpointsMenstrual bleedingMean agePlacebo-controlled phase 3 trialPotential long-term treatmentOral GnRH antagonistSecondary efficacy assessmentsTrial subjectsTRIAL REGISTRATION NUMBERDifferent treatment regimensLong-term treatmentPARTICIPANTS/MATERIALSROLE OF CHANCEMaintenance of effectsSymptom recurrenceSecondary efficacySymptomatic improvementWeek 24Anemic patientsImpact of Endometriosis on Life-Course Potential: A Narrative Review
Missmer SA, Tu FF, Agarwal SK, Chapron C, Soliman AM, Chiuve S, Eichner S, Flores-Caldera I, Horne AW, Kimball AB, Laufer MR, Leyland N, Singh SS, Taylor HS, As-Sanie S. Impact of Endometriosis on Life-Course Potential: A Narrative Review. International Journal Of General Medicine 2021, 14: 9-25. PMID: 33442286, PMCID: PMC7800443, DOI: 10.2147/ijgm.s261139.Peer-Reviewed Original ResearchLife domain satisfactionLife courseFulfilling relationshipsFuture research directionsLife goalsMental healthLives of individualsOne's lifeCareer choiceSexual functioningNarrative reviewProfound negative influenceSocial activitiesTime of lifeDaily challengesWork productivityResearch directionsNegative influenceLife course approachQuality of lifeIndividualsFunctioningEducational opportunitiesLifeSatisfaction
2020
A Clinician's Guide to the Treatment of Endometriosis with Elagolix
Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS. A Clinician's Guide to the Treatment of Endometriosis with Elagolix. Journal Of Women's Health 2020, 30: 569-578. PMID: 32975461, PMCID: PMC8064963, DOI: 10.1089/jwh.2019.8096.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painQuality of lifeGonadotropin-releasing hormone receptor antagonistBaseline clinical factorsModulation of estradiolIntolerable side effectsNew oral therapiesTreatment of endometriosisAvailable treatment optionsHormone receptor antagonistIndividualization of treatmentHypoestrogenic effectsRescue analgesicsPelvic painGnRH agonistOral therapyClinical factorsPain managementClinical evidenceTreatment optionsDosing optionsReceptor antagonistInsufficient efficacyClinician's GuideSide effectsElagolix in the treatment of endometriosis: impact beyond pain symptoms
Archer DF, Soliman AM, Agarwal SK, Taylor HS. Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances In Reproductive Health 2020, 14: 2633494120964517. PMID: 33294846, PMCID: PMC7708701, DOI: 10.1177/2633494120964517.Peer-Reviewed Original ResearchPain symptomsSystemic manifestationsOral gonadotropin-releasing hormone receptor antagonistGonadotropin-releasing hormone receptor antagonistTreatment of endometriosisHormone receptor antagonistQuality of lifePelvic painSevere painCommon symptomsReceptor antagonistEndometriosisElagolixBeneficial effectsSymptomsPainManifestationsOutcomesPatientsWorkplace effectsAntagonistDiseaseWomen
2019
Impact of Elagolix on Quality of Life Among Endometriosis Patients: A Pooled Analysis of 2 Phase III Clinical Trials [13J]
Taylor H, Soliman A, Palac H, Surrey E. Impact of Elagolix on Quality of Life Among Endometriosis Patients: A Pooled Analysis of 2 Phase III Clinical Trials [13J]. Obstetrics And Gynecology 2019, 133: 110-110. DOI: 10.1097/01.aog.0000558829.95268.69.Peer-Reviewed Original ResearchSevere painMonth 3Scale scoreGonadotrophin-releasing hormone antagonistSevere endometriosis-associated painPhase III clinical trialsEndometriosis Health ProfileEndometriosis-associated painPhase III randomizedPlacebo-controlled trialEndometriosis-associated symptomsHealth-related qualityDose-dependent fashionQuality of lifePremenopausal womenHRQL questionnairesMonth 6EHP-30Endometriosis patientsPooled analysisClinical trialsMonths 1Health profileBaseline scoresElagolixClinical diagnosis of endometriosis: a call to action
Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, Singh SS, Taylor HS. Clinical diagnosis of endometriosis: a call to action. American Journal Of Obstetrics And Gynecology 2019, 220: 354.e1-354.e12. PMID: 30625295, DOI: 10.1016/j.ajog.2018.12.039.Peer-Reviewed Original ResearchConceptsEndometriosis diagnosisHealthcare providersClinical diagnosisEarly effective managementFirst symptom onsetWomen's healthcare providersQuality of lifeInvasive surgical proceduresPelvic painSymptom onsetDiagnostic delayTimely referralAdverse sequelaeAssociated painSurgical findingsClinical findingsSurgical diagnosisUnderlying conditionPatient educationSurgical proceduresPelvic lesionsHeterogeneous diseaseDiverse symptomatologyPhysicians' approachEndometriosis
2018
86 Elagolix Reduced Dyspareunia and Improved Health-Related Quality of Life in Premenopausal Women with Endometriosis-Associated Pain
Leyland N, Taylor H, Archer D, Peloso P, Schwefel B, Soliman A, Martinez M, Abrao M. 86 Elagolix Reduced Dyspareunia and Improved Health-Related Quality of Life in Premenopausal Women with Endometriosis-Associated Pain. Journal Of Minimally Invasive Gynecology 2018, 25: s55-s56. DOI: 10.1016/j.jmig.2018.09.093.Peer-Reviewed Original ResearchPIH25 Impact of Elagolix on Health-Related Quality of Life Among Patients with Moderate to Severe Endometriosis-Associated Pain: Analysis of EQ-5D-5L Data from a Phase III Randomized Controlled Trial
Agarwal S, Soliman A, Schwefel B, Peloso P, Surrey E, Taylor H. PIH25 Impact of Elagolix on Health-Related Quality of Life Among Patients with Moderate to Severe Endometriosis-Associated Pain: Analysis of EQ-5D-5L Data from a Phase III Randomized Controlled Trial. Value In Health 2018, 21: s144-s145. DOI: 10.1016/j.jval.2018.04.1014.Peer-Reviewed Original Research
2017
Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)
Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017, 177: 1471-1479. PMID: 28846767, PMCID: PMC5710212, DOI: 10.1001/jamainternmed.2017.3877.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleFollow-Up StudiesGlucuronatesHumansMiddle AgedPostmenopauseProgesteroneProgestinsProspective StudiesPsychiatric Status Rating ScalesQuality of LifeRisk FactorsSexual Dysfunction, PhysiologicalTime FactorsWomen's HealthConceptsKronos Early Estrogen Prevention StudyLow sexual functionTransdermal estrogen therapySexual functionAncillary studiesEstrogen therapyPostmenopausal womenPrevention StudyT-E2Female Sexual Function InventoryOral conjugated equine estrogenOverall scoreLower FSFI scoresEarly postmenopausal womenMenopausal hormone therapyPlacebo-controlled trialOral micronized progesteroneConjugated equine estrogensSexual Function InventoryLast menstrual periodEffects of OralQuality of lifeProportion of womenSymptoms of distressMicronized progesterone
2016
World Endometriosis Society consensus on the classification of endometriosis
Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, Bush D, Kiesel L, Tamimi R, Sharpe-Timms KL, Rombauts L, Giudice LC, Consortium F. World Endometriosis Society consensus on the classification of endometriosis. Human Reproduction 2016, 32: 315-324. PMID: 27920089, DOI: 10.1093/humrep/dew293.Peer-Reviewed Original ResearchConceptsClassification of endometriosisConsensus statementWorld Endometriosis SocietyConsensus meetingMerck SeronoBayer PharmaAvailable evidenceConsensus processWorld Endometriosis Research Foundation Endometriosis PhenomeAppropriate therapeutic optionCase of surgeryClinical data collection toolsPARTICIPANTS/MATERIALSInternational consensus statementROLE OF CHANCEHealth care providersQuality of lifeDifferent consensus statementsBiobanking Harmonisation ProjectPelvic painDisease recurrencePelvic adhesionsTherapeutic optionsMonash IVFClassification systemSexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment
Pluchino N, Wenger JM, Petignat P, Tal R, Bolmont M, Taylor HS, Bianchi-Demicheli F. Sexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment. Human Reproduction Update 2016, 22: 762-774. PMID: 27591248, DOI: 10.1093/humupd/dmw031.Peer-Reviewed Original ResearchConceptsSexual functionEndometriosis patientsPresence of dyspareuniaChronic pelvic painPresence of endometriosisEffect of surgeryOverall sexual functionEffect of endometriosisHalf of womenConsequence of treatmentQuality of lifeSystematic literature searchHealth care interventionsPelvic painDeep dyspareuniaSurgical treatmentMental comorbiditiesGynecologic disordersSexual painHormonal factorsHormonal treatmentMedical conditionsEndometriosisCoital painAdvanced stageThe impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire
Taylor H, Surrey E, Soliman A, Castelli-Haley J, Rowan J, Chwalisz K, Thomas J, Schwefel B, Williams L, Jain R. The impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire. Fertility And Sterility 2016, 106: e93. DOI: 10.1016/j.fertnstert.2016.07.271.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply